Page last updated: 2024-08-24

adenosine and elinogrel

adenosine has been researched along with elinogrel in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's15 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cattaneo, M; Podda, GM1
White, HD1
Cattaneo, M1
Storey, RF1
Moliterno, DJ; Rajan, L1
Contractor, H; Ruparelia, N1
Barn, K; Steinhubl, SR1
Bernlochner, I; Sibbing, D1
Serebruany, VL1
Schrör, K1
Augoustides, JG; Lane, B; Patel, PA1
DiNicolantonio, JJ; Serebruany, VL; Sibbing, D1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ1
Caldeira, D; Ferreira, JJ; Pinto, FJ1
Drebes, A; Klonaris, C; Liakakos, T; Matheiken, S; Patelis, N1

Reviews

12 review(s) available for adenosine and elinogrel

ArticleYear
State of the art of new P2Y12 antagonists.
    Internal and emergency medicine, 2010, Volume: 5, Issue:5

    Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine

2010
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
    Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1

    Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine

2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
    Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1

    Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
    Current cardiology reports, 2011, Volume: 13, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine

2011
Advances in antiplatelet therapy for acute coronary syndromes.
    Postgraduate medical journal, 2012, Volume: 88, Issue:1041

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome

2012
A brief review of the past and future of platelet P2Y12 antagonist.
    Coronary artery disease, 2012, Volume: 23, Issue:6

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine

2012
Thienopyridines and other ADP-receptor antagonists.
    Handbook of experimental pharmacology, 2012, Issue:210

    Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine

2012
Progress in platelet blockers: the target is the P2Y12 receptor.
    Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:3

    Topics: Adenosine; Adenosine Monophosphate; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor

2013
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
    Cardiology, 2014, Volume: 127, Issue:1

    Topics: Acute Lung Injury; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Sulfonamides; Ticagrelor; Ticlopidine; Transfusion Reaction

2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Atherosclerosis, 2014, Volume: 233, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine

2014
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:4

    Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine

2014
Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents.
    Current pharmaceutical design, 2016, Volume: 22, Issue:29

    Topics: Adenosine; Adenosine Monophosphate; Imines; Lactones; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Quinazolinones; Sulfonamides; Ticagrelor

2016

Other Studies

3 other study(ies) available for adenosine and elinogrel

ArticleYear
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    American heart journal, 2011, Volume: 161, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine

2011
Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:6

    Topics: Acute Lung Injury; Adenosine; Blood Platelets; Dyspnea; Humans; Models, Biological; Platelet Aggregation Inhibitors; Quinazolinones; Sulfonamides; Syndrome; Ticagrelor; Transfusion Reaction

2012
'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' - a hypothesis that remains unproven.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:6

    Topics: Acute Lung Injury; Adenosine; Humans; Platelet Aggregation Inhibitors; Quinazolinones; Sulfonamides; Ticagrelor; Transfusion Reaction

2012